Prof. Dr. med. Dr. h.c. Matthias Tschöp

Institutions/Affiliations (Award Year):

  • President of the Ludwig-Maximilians-University (LMU) Munich

Scientific Award Field:

  • The discovery and development of GLP-1-based multi-receptor therapeutics for the treatment of obesity and diabetes

Impact:

  • The Deciphering the gut-brain axis and spearheading the preclinical and clinical validation of multi-receptor co-agonists, translating basic neuroendocrine science into a new therapeutic paradigm that successfully overcomes the body’s natural resistance to weight loss

Prof. Dr. med. Dr. h.c. Matthias Tschöp

Prof. Dr. med. Dr. h.c. Matthias Tschöp is internationally recognized as one of the leading pioneers in metabolic medicine. His groundbreaking research into the hormonal regulation of appetite and energy balance, beginning with the discovery of the role of the hunger hormone ghrelin, fundamentally transformed our understanding of obesity as a biological disease.

Driven by the vision of developing effective hormone-based therapies, he has helped pave the way for a new generation of treatments for obesity and type 2 diabetes.

In recognition of his transformative contributions to metabolic medicine, he was honored as a Laureate of the Broermann Medical Innovation Award 2026.

Scientific Contribution: The GLP-1 Revolution

Tschöp’s research has advanced our understanding of how hormones and the brain regulate appetite, satiety, and body weight. Early in his career, he helped establish the role of the stomach-derived hormone ghrelin in stimulating food intake and promoting weight gain. This work provided important insights into the hormonal signals that link the gut to the brain.

Together with Richard DiMarchi, Tschöp later helped develop and evaluate therapies that target several hormone receptors with a single molecule. Combining DiMarchi’s expertise in peptide chemistry with his own work in metabolic physiology, they demonstrated the potential of dual and triple hormone co-agonists in preclinical studies. Their collaboration helped lay the foundation for a new generation of treatments for obesity and type 2 diabetes, connecting fundamental research on energy balance with therapeutic innovation.

Milestones

Key Publications

Journal: Nature (2000)

Impact: By revealing ghrelin’s central role in driving hunger and fat storage, this study established a new paradigm in metabolic research and opened novel avenues for treating obesity and metabolic disease.

Journal: Nature (2009)

Impact: By pioneering network pharmacology, this work transformed drug discovery by integrating systems biology and polypharmacology, opening new avenues for developing more effective and safer therapies.

Journal: Nature (2012)

Impact: This landmark study introduced targeted hormone co-agonism as a transformative strategy for treating obesity and diabetes, combining enhanced efficacy with reduced side effects.

Journal: Science (2013)

Impact: This landmark study pioneered the development of a single-molecule dual GIP/GLP-1 receptor agonist, demonstrating superior weight loss and glucose control across preclinical models and humans, and laying the scientific foundation for a new generation of highly effective therapies for obesity and type 2 diabetes.

Journal: Nature (2014)

Impact: This landmark study introduced the first rationally designed GLP-1/GIP/glucagon triagonist, demonstrating unprecedented efficacy in reducing obesity, improving glycemic control, and reversing fatty liver disease, thereby establishing multi-receptor hormone therapy as a transformative strategy for treating metabolic disease.

Selected Honors & Recognition

  • Broermann Medical Innovation Award (2026)

    Recognized with the BMIA 2026 for his pioneering work in treating obesity & diabetes, helping millions of people to achieve a healthy weight.

  • Rolf Luft Award (2026)

    Awarded for pioneering discoveries that transformed the understanding and treatment of obesity and metabolic disease.

  • Heinrich Wieland Prize (2023)

    Major recognition of his effortless fight against one of modern society's most pressing diseases.

  • Ernst Schering Prize (2023)

    Recognized for groundbreaking discoveries that revolutionized obesity research and accelerated the development of novel metabolic therapies.

  • Banting Medal for Scientific Achievement Award (2023)

    Highest Achievement in the field of diabetes research and a milestone in his life in the fight against obesity and diabetes.

  • Ernst Jung Prize for Medicine (2021)

    Awarded for groundbreaking research that reshaped the understanding of obesity as a hormone-regulated disease and paved the way for novel therapeutic approaches.

For media inquiries, official press releases, and high-resolution image downloads, please visit our press room